These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12709795)

  • 1. A population-based study on variations in the use of adjuvant systemic therapy on postmenopausal patients with early stage breast cancer.
    Nagel G; Röhrig B; Hoyer H; Wedding U; Katenkamp D
    J Cancer Res Clin Oncol; 2003 Mar; 129(3):183-91. PubMed ID: 12709795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
    Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
    Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
    J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and therapy of premenopausal patients with early-onset breast cancer in Germany.
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Dittmer C; Wedel B; Mebes I; Diedrich K; Fischer D
    Arch Gynecol Obstet; 2012 Aug; 286(2):489-93. PubMed ID: 22491806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal ratio of positive to excised nodes, but not number of positive lymph nodes is better to predict group to avoid chemotherapy among postmenopausal ER-positive, lymph node-positive T1-T2 breast cancer patients.
    Jia XQ; Hong Q; Cheng JY; Li JW; Wang YJ; Mo M; Shao ZM; Shen ZZ; Liu GY
    J Cancer Res Ther; 2015; 11(4):740-5. PubMed ID: 26881511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative margin status improves local control in conservatively managed breast cancer patients.
    Obedian E; Haffty BG
    Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer.
    Guadagnoli E; Shapiro C; Gurwitz JH; Silliman RA; Weeks JC; Borbas C; Soumerai SB
    J Clin Oncol; 1997 Jun; 15(6):2338-44. PubMed ID: 9196148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy.
    Wo JY; Taghian AG; Nguyen PL; Raad RA; Sreedhara M; Bellon JR; Wong JS; Gadd MA; Smith BL; Harris JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):188-96. PubMed ID: 20171798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
    Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.